Roswell Park Cancer Institute, Site #029 — Buffalo, New York

Roswell Park Cancer Institute, Site #029 is a clinical research site located in Buffalo, New York, United States 14263.

Crixeo Health Trust Score: 44/100 (POOR). This profile has not yet been claimed by the site owner.

Roswell Park Cancer Institute, Site #029 has participated in 1 clinical trials.

Therapeutic areas: Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Sponsors: Ariad Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 44/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Roswell Park Cancer Institute, Site #029?

Roswell Park Cancer Institute, Site #029 has a Crixeo Trust Score of 44/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Roswell Park Cancer Institute, Site #029 conducted?

Roswell Park Cancer Institute, Site #029 has 1 clinical trials on record. Their work covers Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Is Roswell Park Cancer Institute, Site #029 accredited by Crixeo Health?

Roswell Park Cancer Institute, Site #029 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Roswell Park Cancer Institute, Site #029?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.